Lantheus (NASDAQ:LNTH) Trading Down 5.5% – Should You Sell?

Lantheus Holdings, Inc. (NASDAQ:LNTH) dropped 5.5% during trading on Tuesday . The company traded as low as $92.55 and last traded at $92.90. Approximately 141,442 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 673,070 shares. The stock had previously closed at $98.31.

Wall Street Analyst Weigh In

LNTH has been the subject of several recent analyst reports. JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial restated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Price Performance

The business’s fifty day simple moving average is $91.55 and its 200 day simple moving average is $100.35. The firm has a market capitalization of $6.21 billion, a price-to-earnings ratio of 14.87 and a beta of 0.46.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Lantheus

Institutional investors and hedge funds have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus in the 3rd quarter valued at $25,000. Signaturefd LLC lifted its position in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. purchased a new stake in shares of Lantheus during the third quarter valued at approximately $51,000. Finally, GAMMA Investing LLC lifted its holdings in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after acquiring an additional 146 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.